Pacific Biosciences
PACB
102 hedge funds and large institutions have $245M invested in Pacific Biosciences in 2015 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 42 increasing their positions, 26 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
62% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 26
9% more funds holding
Funds holding: 94 → 102 (+8)
6% more capital invested
Capital invested by funds: $230M → $245M (+$14.7M)
32% less call options, than puts
Call options by funds: $229K | Put options by funds: $335K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$19.6M |
| 2 |
Millennium Management
New York
|
+$7.38M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$5.21M |
| 4 |
Renaissance Technologies
New York
|
+$1.07M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$797K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$9.04M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.04M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.66M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.96M |
| 5 |
JP Morgan Chase
New York
|
-$819K |
PACB Hedge Fund Activity: Q2 2015 in Review
102 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2015, worth a combined $245M — up 6.4% from $230M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PACB positions and 7 closed out — a net gain of 8 holders — while 42 added to existing stakes and 26 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $19.6M. The largest seller was Deerfield Management, cutting an estimated $9.04M.
- 102 institutional investors held Pacific Biosciences (PACB) as of Q2 2015, up from 94 in Q1 2015.
- Funds reported $245M of Pacific Biosciences stock for Q2 2015, up 6.4% quarter-over-quarter.
- 15 funds opened new Pacific Biosciences positions in Q2 2015 and 7 closed out, a net change of +8 holders.
- The largest Pacific Biosciences buyer in Q2 2015 was Consonance Capital Management, an estimated $19.6M added.
- The largest Pacific Biosciences seller in Q2 2015 was Deerfield Management, an estimated $9.04M sold.
Based on aggregated 13F filings for Q2 2015.